Overview

Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris

Status:
Recruiting
Trial end date:
2023-02-13
Target enrollment:
Participant gender:
Summary
This trial investigates the safety and tolerability of three different doses and two types of administration routes of a C. acnes vaccine (ORI-A-ce001) in subjects with acne vulgaris.
Phase:
Phase 1
Details
Lead Sponsor:
Origimm Biotechnology GmbH